Pfizer gains generics, injectables in InnoPharma buy
This article was originally published in Scrip
Pfizer will pay $225m in upfront cash and up to $135m in milestone fees to buy InnoPharma, a private Piscataway, New Jersey-based company with 10 approved generic medicines, 19 more under US FDA review, and 30 injectable and ophthalmic products under development.
You may also be interested in...
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.